Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease
Autor: | Christian P. Selinger, Alexander C. Ford, David J. Gracie, Keeley M Fairbrass |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty Physiology Rome Inflammatory bowel disease Irritable Bowel Syndrome Quality of life Surveys and Questionnaires Internal medicine Prevalence Humans Medicine Irritable bowel syndrome Depression (differential diagnoses) Endocrine and Autonomic Systems business.industry digestive oral and skin physiology Gastroenterology Inflammatory Bowel Diseases medicine.disease digestive system diseases Analgesics Opioid Mood disorders Chronic Disease Cohort Quality of Life Anxiety Female medicine.symptom business Somatization |
Zdroj: | Neurogastroenterology & Motility. 34 |
ISSN: | 1365-2982 1350-1925 |
Popis: | BACKGROUND Irritable bowel syndrome (IBS)-type symptoms are common in inflammatory bowel disease (IBD), but few studies have examined the prevalence and impact of IBS-type symptoms in IBD according to Rome IV criteria. METHODS We collected demographic, symptom (Rome III, Rome IV, and clinical disease activity indices), psychological (anxiety, depression, and somatization), and quality of life data from 973 IBD patients. Medical records were reviewed to document disease type, extent/location, behavior, medical therapy, and antidepressant or opioid use. We compared characteristics of individuals with no IBS-type symptoms, Rome III IBS-type symptoms, and Rome IV IBS-type symptoms. KEY RESULTS In total, 302 (31.0%) patients met the Rome III criteria for IBS, and 172 (17.7%) met Rome IV criteria. Those with IBS-type symptoms were younger, more likely to be female, and had higher rates of antidepressant (p = 0.006) or opioid use (p = 0.001). Rome IV IBS-type symptoms were associated with symptoms of mood disorders, flare of disease activity, and lower quality of life scores (p |
Databáze: | OpenAIRE |
Externí odkaz: |